Browse the evidence

Semaglutide 2.4 mg once weekly significantly reduces major adverse cardiovascular events (MACE) and all-cause mortality in individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD), regardless of diabetes status.

If you have obesity and established heart disease, semaglutide 2.4 mg once weekly is a preferred first-line treatment to significantly reduce your risk of heart attacks, strokes, and death, even if you do not have diabetes. This should be combined with lifestyle therapy.

Semaglutide 2.4 mg once weekly is the preferred first-line anti-obesity medication for individuals with obesity and chronic kidney disease (CKD), including non-diabetic populations, due to significant reductions in renal endpoint progression.

If you have obesity and chronic kidney disease, semaglutide 2.4 mg once weekly is the preferred first-line treatment to significantly slow kidney function decline and reduce the risk of needing dialysis or kidney replacement therapy, even if you do not have diabetes.

Tirzepatide 15 mg once weekly is preferred for individuals with obesity and prediabetes when greater weight loss is needed, achieving a 94% risk reduction in diabetes progression over 72 weeks.

If you have obesity and prediabetes, tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce your risk of developing type 2 diabetes and achieve substantial weight loss, especially if lifestyle changes alone are not enough.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and triple agonists (e.g., retatrutide) produce significantly greater reductions in body weight and HbA1c compared to selective GLP-1 receptor agonists or placebo in individuals with type 2 diabetes and obesity.

For individuals with obesity or type 2 diabetes, dual GIP/GLP-1 agonists like tirzepatide offer superior weight loss and blood sugar control compared to older GLP-1-only drugs. Treatment typically starts at a low dose (2.5 mg weekly) and increases gradually to 5, 10, or 15 mg to manage side effects. Clinical trials show up to 20% body weight reduction in non-diabetic obese adults over two years.

Tirzepatide (15mg weekly) achieves 20.9% weight loss, with 50-57% of users losing >= 20% body weight, rivaling bariatric surgery.

Tirzepatide 15mg weekly can lead to ~21% weight loss. Over half of users lose 20% or more. This is a powerful option for those with comorbidities.

Once-weekly subcutaneous semaglutide 2.4 mg produces significantly greater weight loss in adults without type 2 diabetes (mean -11.57%) compared to those with type 2 diabetes (mean -6.34%).

If you have Type 2 Diabetes, expect semaglutide 2.4 mg to work, but anticipate roughly half the weight loss percentage compared to someone without diabetes. This is due to metabolic factors like insulin resistance and 'glycemic buffering' (where improved blood sugar control reduces calorie loss through urine). Manage expectations by focusing on metabolic health benefits alongside weight metrics, as the drug remains clinically effective for both groups.

GLP-1-based peptide therapeutics achieve 15–25% body weight loss with once-weekly dosing, surpassing the efficacy of previous small-molecule drugs and matching bariatric surgery outcomes.

GLP-1 therapies like semaglutide and tirzepatide offer a powerful medical option for obesity, achieving 15-25% weight loss with once-weekly injections. This efficacy rivals bariatric surgery but without the surgical risks. However, these drugs require ongoing use to maintain results, and access can be limited by cost and supply. Consult a healthcare provider to determine if this treatment is appropriate for your specific health profile.

Dual and poly-agonists (e.g., Tirzepatide) targeting multiple receptors (GLP-1R, GIPR) provide superior weight loss compared to single-agonist GLP-1 therapies.

Dual-agonist drugs like Tirzepatide target both GLP-1 and GIP receptors, offering greater weight loss (up to 21%) than single-agonist GLP-1 drugs. This approach leverages multiple hormonal pathways for enhanced efficacy. It is a once-weekly injection suitable for those who need more potent weight loss support.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (15-23%) and should be considered for patients with higher weight-loss goals or specific comorbidities like MASH or severe OSA.

If you have obesity and related health issues like sleep apnea or fatty liver, your doctor might recommend injectable medications like semaglutide or tirzepatide. These can lead to significant weight loss (15-23%) when combined with lifestyle changes. Discuss the pros and cons of injectable vs. oral options with your provider.

Discontinuation of obesity medications leads to weight regain and reversal of cardiometabolic improvements, necessitating long-term treatment.

If you are taking obesity medications, you likely need to continue them long-term to maintain weight loss. Stopping the medication often leads to weight regain. Talk to your doctor about managing costs and side effects to stay on treatment.

Semaglutide 2.4 mg weekly produces a sustained, slowly decaying weight loss effect in adults with obesity, with an estimated 14.9% reduction in body weight over 68 weeks compared to placebo.

Take 2.4 mg of semaglutide once weekly as part of a lifestyle intervention. Expect significant weight loss (around 15% over 68 weeks) compared to placebo. Adherence is key, as discontinuation reduces effectiveness.

Pharmacotherapy using GLP-1 receptor agonists (semaglutide) or dual GIP/GLP-1 agonists (tirzepatide) produces significant weight loss (10-20%) and improves obesity-related comorbidities, serving as a necessary adjunct to lifestyle intervention for patients with BMI ≥30 kg/m2 or ≥27 kg/m2 with complications.

If you have a BMI over 30 (or over 27 with health issues like high blood pressure or diabetes), lifestyle changes alone often aren't enough because your body fights weight loss. Medications like semaglutide or tirzepatide, taken once weekly, can help you lose 10-20% of your body weight and improve your health conditions. These are long-term treatments; stopping them usually leads to regaining the weight. If cost is a barrier, ask your doctor about starting at a lower dose, which may still be effective.

Discontinuation of obesity pharmacotherapy leads to significant weight regain and recurrence of metabolic benefits loss, necessitating lifelong treatment or intensive lifestyle support.

Obesity is a chronic condition, much like high blood pressure. If you stop your medication, you will likely regain the weight and your health markers (like blood sugar and blood pressure) may worsen. Most people need to stay on treatment long-term to maintain their health benefits. If you want to stop, discuss a plan with your doctor, as weight regain is very common.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to selective GLP-1 receptor agonists by improving beta-cell function, enhancing insulin sensitivity independent of weight loss, and modulating central appetite regulation.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective for lowering blood sugar and reducing body weight, often outperforming older GLP-1 drugs. It improves insulin sensitivity directly, not just through weight loss. Common side effects like nausea may be less severe due to the GIP component. It is prescribed for Type 2 Diabetes and Obesity.

Protein supplementation augments strength and hypertrophy.

If you are doing resistance training, protein supplementation can help you build more strength and muscle.

Creatine supplementation augments strength.

Creatine supplementation is an effective way to increase strength when combined with resistance training.

Oral GLP-1 receptor agonists (orforglipron and oral semaglutide) produce clinically meaningful double-digit weight loss (11.2–13.6%) and cardiometabolic improvements in adults with obesity without diabetes, offering a viable alternative to injectable therapies.

Oral GLP-1 medications like orforglipron and oral semaglutide are now proven to help adults with obesity lose significant weight (11-13%) and improve heart health markers without needing injections. If you struggle with needles or prefer a pill, these are viable, effective options, though you should discuss specific dosing rules and potential side effects like nausea with your doctor.

Adherence to the DASH dietary pattern reduces systolic blood pressure by 1–13 mm Hg and diastolic blood pressure by 1–10 mm Hg, with effects amplified when combined with weight loss or sodium restriction.

Adopt the DASH diet by prioritizing fruits, vegetables, low-fat dairy, and whole grains while limiting saturated fats and sugars. This approach is clinically proven to lower blood pressure significantly, often matching the effectiveness of standard blood pressure medications, especially if you also manage your weight and sodium intake.

Restricting daily sodium intake to approximately 2 grams (5 grams of salt) reduces systolic blood pressure by approximately 7 mm Hg in hypertensive individuals.

Limit your daily sodium intake to about 2 grams (roughly one teaspoon of salt). Focus on avoiding processed and restaurant foods, which are the main sources of sodium, and use natural ingredients and herbs for flavoring. This single change can lower blood pressure by an amount comparable to taking a blood pressure medication.

Regular aerobic exercise of at least 150 minutes per week reduces systolic blood pressure by 4–7 mm Hg and diastolic blood pressure by 3–4 mm Hg.

Aim for at least 150 minutes of moderate-intensity aerobic exercise per week, spread over 5-7 days. This could be brisk walking, cycling, or swimming. This amount of exercise can lower your blood pressure by an amount similar to taking a blood pressure medication. If you have uncontrolled high blood pressure, avoid high-intensity exercise until it is managed.

Sustained weight loss of at least 5% is recommended for individuals with overweight or obesity at moderate atherosclerotic cardiovascular disease (ASCVD) risk to reduce cardiometabolic risk factors and delay type 2 diabetes onset.

If you are at moderate cardiovascular risk, aim to lose just 5% of your body weight through a daily calorie deficit of 500-750 calories and 150 minutes of weekly exercise. This modest loss is scientifically proven to significantly lower your blood pressure, improve cholesterol, and drastically reduce your risk of developing type 2 diabetes.

Treatment with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, liraglutide 3.0 mg) or GLP-1/GIP co-agonists (tirzepatide) is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce weight and cardiovascular risk factors.

If you have overweight or obesity and are at moderate or high cardiovascular risk, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are recommended treatments that significantly reduce weight and cardiovascular risk factors, often more effectively than lifestyle changes alone.

Semaglutide, a GLP-1 receptor agonist, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity through glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation.

Semaglutide is a prescription medication for T2DM and obesity that works by mimicking a gut hormone to regulate blood sugar, reduce appetite, and slow digestion. It is available as a weekly injection or a daily pill. Clinical trials show significant weight loss (4-15%) and improved blood sugar control (HbA1c reduction of 1.0-1.8%). Common side effects include nausea, which often improves over time. It is recommended for patients with cardiovascular risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.

If you have Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection that lowers blood sugar and helps you lose significant weight, often outperforming other common diabetes medications and insulin. While it can cause temporary stomach issues like nausea, these are usually mild and manageable, and the long-term benefits for your heart, kidneys, and overall metabolic health are substantial.